Esperion Therapeutics (ESPR) Reports Q1 Loss, Tops Revenue Estimates

Esperion Therapeutics (ESPR) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to earnings of $0.34 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -16.67%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.14 per share when it actually produced a loss of $0.10, delivering a surprise of 28.57%.Over the last four quart ...